| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Aurélie A Boucher, Glenn E Hunt, Jacques Micheau, Xufeng Huang, Iain S McGregor, Tim Karl, Jonathon C Arnol. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. The international journal of neuropsychopharmacology. vol 14. issue 5. 2012-01-06. PMID:20701826. |
the schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. |
2012-01-06 |
2023-08-12 |
mouse |
| Aurélie A Boucher, Glenn E Hunt, Jacques Micheau, Xufeng Huang, Iain S McGregor, Tim Karl, Jonathon C Arnol. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. The international journal of neuropsychopharmacology. vol 14. issue 5. 2012-01-06. PMID:20701826. |
in this study we aim to show that the schizophrenia susceptibility gene neuregulin 1 (nrg1) modulates the development of tolerance to cannabinoids in mice. |
2012-01-06 |
2023-08-12 |
mouse |
| D Minocci, J Massei, A Martino, M Milianti, L Piz, D Di Bello, A Sbrana, E Martinotti, A M Rossi, P Nier. Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. Journal of affective disorders. vol 134. issue 1-3. 2011-12-21. PMID:21658778. |
several studies provided evidence that the endocannabinoid system (ecs) is involved in psychiatric diseases, like major depression, schizophrenia and bipolar disorder (bd), mainly focusing on cb1 cannabinoid receptor, and faah, the fatty acid amide hydrolase involved in endocannabinoid metabolism. |
2011-12-21 |
2023-08-12 |
Not clear |
| Deanna L Kelly, David A Gorelick, Robert R Conley, Douglas L Boggs, Jared Linthicum, Fang Liu, Stephanie Feldman, M Patricia Ball, Heidi J Wehring, Robert P McMahon, Marilyn A Huestis, Stephen J Heishman, Kimberly R Warren, Robert W Buchana. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. Journal of clinical psychopharmacology. vol 31. issue 1. 2011-10-13. PMID:21192149. |
the endocannabinoid system remains a promising target for pharmacotherapy of schizophrenia and obesity. |
2011-10-13 |
2023-08-12 |
human |
| Mark D Black, Rachel J Stevens, Nancy Rogacki, Robert E Featherstone, Yaw Senyah, Odessa Giardino, Beth Borowsky, Jeanne Stemmelin, Caroline Cohen, Philippe Pichat, Michal Arad, Segev Barak, Amaya De Levie, Ina Weiner, Guy Griebel, Geoffrey B Vart. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology. vol 215. issue 1. 2011-08-15. PMID:21181124. |
ave1625, a cannabinoid cb1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. |
2011-08-15 |
2023-08-12 |
Not clear |
| Loris A Chah. TRP channels and psychiatric disorders. Advances in experimental medicine and biology. vol 704. 2011-07-01. PMID:21290337. |
however, the findings that trpc channels are involved in neuronal development and fundamental synaptic mechanisms, and that trpv1 channels play a role in central dopaminergic and cannabinoid mechanisms is suggestive of potential roles of these channels in schizophrenia. |
2011-07-01 |
2023-08-12 |
human |
| Emanuel Schwarz, Phil Whitfield, Sven Nahnsen, Lan Wang, Hilary Major, F Markus Leweke, Dagmar Koethe, Pietro Lio, Sabine Bah. Alterations of primary fatty acid amides in serum of patients with severe mental illness. Frontiers in bioscience (Elite edition). vol 3. 2011-06-03. PMID:21196311. |
cannabis consumption is a well known risk factor for the onset of schizophrenia and evidence accumulates that the endocannabinoid system may play a central role in the disease etiology. |
2011-06-03 |
2023-08-12 |
human |
| Emanuel Schwarz, Phil Whitfield, Sven Nahnsen, Lan Wang, Hilary Major, F Markus Leweke, Dagmar Koethe, Pietro Lio, Sabine Bah. Alterations of primary fatty acid amides in serum of patients with severe mental illness. Frontiers in bioscience (Elite edition). vol 3. 2011-06-03. PMID:21196311. |
using a clinical bioinformatics approach, we have previously found primary fatty acid amides, which are linked to the endocannabinoid system, to be elevated in drug naive schizophrenia and affective disorder. |
2011-06-03 |
2023-08-12 |
human |
| Emanuel Schwarz, Phil Whitfield, Sven Nahnsen, Lan Wang, Hilary Major, F Markus Leweke, Dagmar Koethe, Pietro Lio, Sabine Bah. Alterations of primary fatty acid amides in serum of patients with severe mental illness. Frontiers in bioscience (Elite edition). vol 3. 2011-06-03. PMID:21196311. |
our findings support the involvement of the endocannabinoid system in the pathology of schizophrenia. |
2011-06-03 |
2023-08-12 |
human |
| Cinzia Guidali, Daniela Viganò, Stefania Petrosino, Erica Zamberletti, Natalia Realini, Giorgio Binelli, Tiziana Rubino, Vincenzo Di Marzo, Daniela Parolar. Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. The international journal of neuropsychopharmacology. vol 14. issue 1. 2011-05-24. PMID:20196921. |
clinical and laboratory studies suggest that the endocannabinoid system is involved in schizophrenia disorders. |
2011-05-24 |
2023-08-12 |
Not clear |
| F Markus Leweke, Miriam Schneide. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. The international journal of neuropsychopharmacology. vol 14. issue 1. 2011-05-24. PMID:20678304. |
chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. |
2011-05-24 |
2023-08-12 |
rat |
| F Markus Leweke, Miriam Schneide. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. The international journal of neuropsychopharmacology. vol 14. issue 1. 2011-05-24. PMID:20678304. |
chronic pubertal cannabinoid treatment in rats has been suggested for modelling aspects of schizophrenia since it results in long-lasting behavioural alterations reflecting certain characteristics of schizophrenia symptomatology. |
2011-05-24 |
2023-08-12 |
rat |
| F Markus Leweke, Miriam Schneide. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. The international journal of neuropsychopharmacology. vol 14. issue 1. 2011-05-24. PMID:20678304. |
furthermore, the present data give further support and validity for the suitability of chronic pubertal cannabinoid administration as an animal model for aspects of schizophrenia. |
2011-05-24 |
2023-08-12 |
rat |
| Mathieu Verdurand, Victoria Stephanie Dalton, Katerina Zavitsano. GABA(A) receptor density is altered by cannabinoid treatment in the hippocampus of adult but not adolescent rats. Brain research. vol 1351. 2011-05-17. PMID:20599838. |
cannabinoids are known to induce transient psychotic symptoms and cognitive dysfunction in healthy individuals and contribute to trigger schizophrenia in vulnerable individuals, particularly during adolescence. |
2011-05-17 |
2023-08-12 |
rat |
| Stephanie A Robinson, Richard E Loiacono, Arthur Christopoulos, Patrick M Sexton, Daniel T Malon. The effect of social isolation on rat brain expression of genes associated with endocannabinoid signaling. Brain research. vol 1343. 2011-02-15. PMID:20430015. |
also, a dysregulation of the endocannabinoid system has been implicated in schizophrenia. |
2011-02-15 |
2023-08-12 |
rat |
| R Andrew Sewell, Patrick D Skosnik, Icelini Garcia-Sosa, Mohini Ranganathan, Deepak Cyril D'Souz. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32 Suppl 1. 2011-02-03. PMID:20512267. |
[behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. |
2011-02-03 |
2023-08-12 |
Not clear |
| R Andrew Sewell, Patrick D Skosnik, Icelini Garcia-Sosa, Mohini Ranganathan, Deepak Cyril D'Souz. [Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia]. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 32 Suppl 1. 2011-02-03. PMID:20512267. |
cannabinoids also produce some psychophysiological deficits also known to be present in schizophrenia. |
2011-02-03 |
2023-08-12 |
Not clear |
| F Markus Lewek. Schizophrenia. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104393. |
since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the potential role of this system in schizophrenia. |
2011-01-04 |
2023-08-12 |
Not clear |
| F Markus Lewek. Schizophrenia. Current topics in behavioral neurosciences. vol 1. 2011-01-04. PMID:21104393. |
a possible neurobiological mechanism for the deleterious influence of cannabis use in schizophrenia is discussed, involving the disruption of endogenous cannabinoid signalling and function. |
2011-01-04 |
2023-08-12 |
Not clear |
| Dean F Wong, Hiroto Kuwabara, Andrew G Horti, Vanessa Raymont, James Brasic, Maria Guevara, Weiguo Ye, Robert F Dannals, Hayden T Ravert, Ayon Nandi, Arman Rahmim, Jeffrey E Ming, Igor Grachev, Christine Roy, Nicola Cascell. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage. vol 52. issue 4. 2010-12-17. PMID:20406692. |
quantification of cerebral cannabinoid receptors subtype 1 (cb1) in healthy subjects and schizophrenia by the novel pet radioligand [11c]omar. |
2010-12-17 |
2023-08-12 |
human |